ERBB2 and breast cancer: An accurate and reproducible detection of HER2 protein overexpression and/or gene amplification plays a key role in determining the future course of BC treatment, especially in the light of recent data which have demonstrated promising clinical efficacy of novel biological agents, such as the anti-HER2 MoAbs Pertuzumab and TDM1 [3,4].